CADL (STOCKS)
Candel Therapeutics, Inc. Common Stock
$8.073700
+0.103700 (+1.30%)
Prev close: $7.970000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Paul-Peter Tak
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $585.06M
- Employees
- 38
- P/E (TTM)
- -8.17
- P/B (TTM)
- 4.24
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
9
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.14 | $-0.32 | +0.1832 | +56.68% |
|
Dec 2025 (Q4)
|
$-0.54 | $-0.25 | -0.2892 | -115.31% |
|
Sep 2025 (Q3)
|
$-0.21 | $-0.19 | -0.0212 | -11.23% |
|
Jun 2025 (Q2)
|
$-0.09 | $-0.17 | +0.0834 | +48.10% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $2.00M |
| Operating Expenses | $56.42M |
| Research and Development | $36.32M |
| Other Operating Expenses | $20.10M |
| Operating Income/Loss | -$56.42M |
| Income/Loss From Continuing Operations After Tax | -$54.42M |
| Income/Loss From Continuing Operations Before Tax | -$54.42M |
| Interest Expense, Operating | $3.38M |
| Net Income/Loss | -$54.42M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$54.42M |
| Net Income/Loss Available To Common Stockholders, Basic | -$54.42M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.99 |
| Diluted Earnings Per Share | -$0.99 |
| Basic Average Shares | 169,399,804 |
| Diluted Average Shares | 169,399,804 |
| Assets | $201.92M |
| Current Assets | $197.75M |
| Noncurrent Assets | $4.17M |
| Fixed Assets | $2.08M |
| Other Non-current Assets | $2.09M |
| Liabilities | $63.89M |
| Current Liabilities | $7.05M |
| Accounts Payable | $3.04M |
| Wages | $1.36M |
| Other Current Liabilities | $2.66M |
| Noncurrent Liabilities | $56.84M |
| Equity | $138.03M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $138.03M |
| Liabilities And Equity | $201.92M |
| Net Cash Flow From Operating Activities | -$47.73M |
| Net Cash Flow From Operating Activities, Continuing | -$47.73M |
| Net Cash Flow From Investing Activities | -$1.23M |
| Net Cash Flow From Investing Activities, Continuing | -$1.23M |
| Net Cash Flow From Financing Activities | $151.78M |
| Net Cash Flow From Financing Activities, Continuing | $151.78M |
| Net Cash Flow | $102.82M |
| Net Cash Flow, Continuing | $102.82M |
| Comprehensive Income/Loss | -$54.42M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$54.42M |
| Other Comprehensive Income/Loss | $0.00 |